$23.5MSeries C, 13 March 2026
MustBio closed a ₩35B Series C to fund clinical development of IL-2 based MB5 and IL-21 based MB7, bringing total funding to ₩63.5B.
- Amount
- $23.5M
- Stage
- Series C
- Announced
- 13 March 2026
- Lead
- Atinum Investment
- Other investors
- BNH Investment, Korea Investment Partners, Premier Partners, Partners Investment, Korea Development Bank
- Use of funds
- MustBio closed a ₩35B Series C to fund clinical development of IL-2 based MB5 and IL-21 based MB7, bringing total funding to ₩63.5B.
- Checked
- Amount and date checked against the press source
- Source
- MustBio raises ₩35B Series C for next-gen immuno-oncology unicornfactory.co.kr